Last checked at 
LONDON (Alliance News) - Genedrive PLC on Thursday said it will participate in an international multicentre trial to assess the impact of out-reach HCV diagnostics and therapy in a pharmacy setting versus conventional treatment pathways.
The molecular diagnostics company said the study will be led by John Dillon, professor of hepatology & gastroenterology at the University of Dundee. It will be funded by biopharmaceutical company AbbVie.
The trial will cover up to 40 pharmacies across three sites in Scotland, Wales, and Australia and will involve 140 patience undergoing opiate substitute therapy.
Genedrive said the study will examine whether the international multicentre trial pathway is more cost-effective than the conventional pathway, from the perspective of the NHS UK and Medicare Australia. It will also determine if more HCV RNA positive people can be treated and cured.
"The advancement of molecular diagnostics to the point of need will provide faster treatment decisions to patients who have difficulty accessing traditional centralised services," said Gnedrive Chief Executive David Budd.
"It is vital that if we are to eliminate HCV, we must find novel ways of using paradigm shifting technology like Genedrive HCV-ID in care pathways, to bring cure of HCV to the people who need it most," added Dillon.
Genedrive shares were untraded on Thursday, last quoted at 20.72 pence each.
